biostudies-literatureMatossian MDNIBIB NIH HHSNCI NIH HHSNational Institutes of HealthNational Institute of General Medical SciencesNIGMS NIH HHSNIH HHS127-144https://www.ebi.ac.uk/biostudies/studies/S-EPMC8732292biostudies-literatureUnknown24(1)Metaplastic breast carcinoma (MBC) is a rare breast cancer subtype with rapid growth, high rates of metastasis, recurrence and drug resistance, and diverse molecular and histological heterogeneity. Patient-derived xenografts (PDXs) provide a translational tool and physiologically relevant system to evaluate tumor biology of rare subtypes. Here, we provide an in-depth comprehensive characterization of a new PDX model for MBC, TU-BcX-4IC. TU-BcX-4IC is a clinically aggressive tumor exhibiting rapid growth in vivo, spontaneous metastases, and elevated levels of cell-free DNA and circulating tumor cell DNA. Relative chemosensitivity of primary cells derived from TU-BcX-4IC was performed using the National Cancer Institute (NCI) oncology drug set, crystal violet staining, and cytotoxic live/deaClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of MexicoIn-depth characterization of a new patient-derived xenograft model for metaplastic breast carcinoma to identify viable biologic targets and patterns of matrix evolution within rare tumor types.PMC8732292R01 CA174785T34 GM136452T32 EB0276321R15CA176496-01A1R01-CA125806-04R15 CA176496U54 GM104940R01 CA125806R01-CA174785-A1Zea AHBrown HOchoa AElliott SBaddoo MBurks HEHebert KLSirenko OIzadpanah RZabaleta JSabol RAMartin ECWright MKWindsor GOMiele LMoroz KMatossian MDKing CTAlzoubi MSChang TFlemington ENguyen KBunnell BARiker AIBurow MESinha SWathieu HBursavich JBLau FCromwell EFSavoie JJHam AMCollins-Burow BMfalseIn-depth characterization of a new patient-derived xenograft model for metaplastic breast carcinoma to identify viable biologic targets and patterns of matrix evolution within rare tumor types.Metaplastic breast carcinoma (MBC) is a rare breast cancer subtype with rapid growth, high rates of metastasis, recurrence and drug resistance, and diverse molecular and histological heterogeneity. Patient-derived xenografts (PDXs) provide a translational tool and physiologically relevant system to evaluate tumor biology of rare subtypes. Here, we provide an in-depth comprehensive characterization of a new PDX model for MBC, TU-BcX-4IC. TU-BcX-4IC is a clinically aggressive tumor exhibiting rapid growth in vivo, spontaneous metastases, and elevated levels of cell-free DNA and circulating tumor cell DNA. Relative chemosensitivity of primary cells derived from TU-BcX-4IC was performed using the National Cancer Institute (NCI) oncology drug set, crystal violet staining, and cytotoxic live/dea2022-01-01T00:00:00Z2022 Jan2026-06-17T05:13:17.341Z2022-02-11T15:22:54.749ZS-EPMC87322923437018210.1007/s12094-021-02677-8